TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en nuestros pacientes Vía @CircAHA #Trigliceridos #Colesterol #CardioTwitter https://t.co/4ipKByaULi https://t.co/i4VffODqxJ
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Sep 2019 – Sep 2025Where it's discussed
-
News119 articles
-
X / Twitter87 posts
-
YouTube2 videos
-
Facebook2 posts
AI synopsis
What people are saying
Many discussions highlight key studies and their implications, such as the effectiveness of high-dose EPA noted in the REDUCE-IT trial and the comparative futility found in the STRENGTH trial. The tone in these discussions is analytical and intensive, using phrases like 'the benefits of marine-derived omega-3 fatty acids appear to exceed their lipid-lowering effects,' which indicates a serious consideration of the potential clinical impacts this research could have.
The majority of discussions support the article's findings regarding triglyceride lowering and cardiovascular risk reduction, showing a positive consensus.
Posts reflect high interest as participants discuss and analyze various studies and findings related to the publication.
Many discussions delve into detailed comparisons of studies like REDUCE-IT and STRENGTH, indicating a thorough engagement with the content.
Participants express a belief that the findings will significantly influence clinical practices regarding triglyceride management.
Abstract in brief
- The study analyzed randomized controlled trials to assess the relationship between lowering triglycerides and reducing cardiovascular risk, focusing on therapies like fibrates, niacin, and omega-3 fatty acids alongside statins.
- It included data from 374,358 participants, highlighting that while triglyceride-lowering therapies showed varying results in reducing major vascular events, reductions in non-high-density lipoprotein cholesterol (non-HDL-C) and low-density lipoprotein cholesterol (LDL-C) were associated with reduced cardiovascular risks.
- The REDUCE-IT trial, which examined the effects of icosapent ethyl, was noted as a significant outlier in showing a strong impact on reducing cardiovascular events.
Top posts
Most liked on X and BlueskySTRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our meta-analysis in @CircAHA this fall showed that the benefit of omega-3 fatty acids appeared to be in EPA only. @TIMIStudyGroup https://t.co/3qgAwRBbGq https://t.co/vs5vZ2S3Xy
Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected by lipid-lowering alone? Our 49 trial meta-regression sheds light on these questions @circAHA @TIMIStudyGroup @BrighamFellows https://t.co/QXR1nXlg9p https://t.co/ZV0WOFWbAt
Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across multiple #lipid lowering therapeutic classes: Learn more: https://t.co/c1Kzkv82jj #AHAJournals @marstonMD https://t.co/S1b6Keg3qy
Which is more important, LDL-C or triglycerides? 1) LDL-C changes have 4X more impact on CV risk BUT... 2) both LDL-C and TGs are surrogates of atherogenic apoB lipoproteins 3) you want BOTH under control! ignoring either one = playing Russian roulette https://t.co/4am8RVRBS4 https://t.co/nrqFkr7GFL
Association Between TG Lowering and Reduction of CV Risk Across Multiple Lipid-Lowering Therapeutic Classes "Furthermore, benefits of marine-derived omega-3 fatty acids, particularly high-dose EPA, appear to exceed their lipid-lowering effects" $AMRN https://t.co/6RzCgdZnJc
All mentions
Evaluating Cholesterol Ratios and Lipids in Heart Disease Risk Assessment
Are ratios like triglyceridesHDLC or total cholesterolHDLC reliable measures of heart disease risk? This video discusses the strengths and limitations of cholesterol ratios and explores recent genetic research on…
Pemafibrate's Impact on Cardiovascular Risk in Diabetes Patients
This video discusses pemafibrate, a drug that lowers high triglyceride levels and improves lipids. A trial with nearly 10,500 patients showed that while it significantly reduced triglycerides, it did not lead to fewer…
RT @Fizz_DI: TG低下治療のメタ解析(24件の研究、n=197,270)。 ・心血管イベント EPAの追加:RR=0.93 [95%CI: 0.91-0.95] DHAの追加:RR=0.96 [95%CI: 0.89-1.03] Circulation.14…
TG低下治療のメタ解析(24件の研究、n=197,270)。 ・心血管イベント EPAの追加:RR=0.93 [95%CI: 0.91-0.95] DHAの追加:RR=0.96 [95%CI: 0.89-1.03] Circulation.140(16):1308-1317,(2019) PMID:31530008 https://t.co/XLpCQihc80
@WALangProf @PeroneFrancesco @escardio @EAPCPresident @m_piepoli @AboyansV @hansen_phd @ESC_Journals @ESC_Camille @ESC_Lavinia @gbiondizoccai @El_Cavarretta @MichaelPapadak2 @FlavioDascenzi And the correct link!! https://t.co/H7BIwhJFAC.
https://t.co/f9XRhkSo6k https://t.co/39utlykkJC
RT @NutritionMadeS3: Which is more important, LDL-C or triglycerides? 1) LDL-C changes have 4X more impact on CV risk BUT... 2) both LDL-…
RT @NutritionMadeS3: Which is more important, LDL-C or triglycerides? 1) LDL-C changes have 4X more impact on CV risk BUT... 2) both LDL-…
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes | Circulation https://t.co/vdBOy99zJp
Which is more important, LDL-C or triglycerides? 1) LDL-C changes have 4X more impact on CV risk BUT... 2) both LDL-C and TGs are surrogates of atherogenic apoB lipoproteins 3) you want BOTH under control! ignoring either one = playing Russian roulette https://t.co/4am8RVRBS4 https://t.co/nrqFkr7GFL
RT @marstonMD: STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our…
RT @marstonMD: STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our…
RT @marstonMD: STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our…
RT @marstonMD: STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our…
RT @marstonMD: STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our…
RT @marstonMD: STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our…
RT @marstonMD: STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our…
STRENGTH trial stopped early for futility. Unlike REDUCE-IT (4 g EPA), STRENGTH used a combo of EPA and DHA (2 g each). Our meta-analysis in @CircAHA this fall showed that the benefit of omega-3 fatty acids appeared to be in EPA only. @TIMIStudyGroup https://t.co/3qgAwRBbGq https://t.co/vs5vZ2S3Xy
RT @RevistaMFSamfyc: Asociación entre el descenso de triglicéridos y la reducción de riesgo cardiovascular a través de varias clases de ter…
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes | Circulation https://t.co/NS2qWbT253
RT @SABOURETCardio: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeut…
Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes https://t.co/BxGzZ7V1wF
RT @TIMIStudyGroup: Published this week in @CircAHA: TG lowering is associated with lower risk of CV events, but to a lesser extent than LD…
Published this week in @CircAHA: TG lowering is associated with lower risk of CV events, but to a lesser extent than LDL-C lowering. CV benefits of high dose EPA appear to exceed their lipid-lowering effects. @marstonMD https://t.co/Ge0E6xdwjK @DrM_ODonoghue @swiviott https://t.co/ZLDHZ04a13
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
Association Between #Triglyceride Lowering and Reduction of #Cardiovascular Risk Across Multiple #Lipid-Lowering Therapeutic Classes | #Circulation https://t.co/3MxLRYgQfL
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @SABOURETCardio: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeut…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @SABOURETCardio: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeut…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @SABOURETCardio: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeut…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes | Circulation Will TG come back to the party ?
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @gonzaeperez: TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en…
TRIGLICERIDOS Y REDUCCIÓN DEL RIESGO CARDIOVASCULAR No todo es #LDL El colesterol No-HDL es un valor que debemos mirar en nuestros pacientes Vía @CircAHA #Trigliceridos #Colesterol #CardioTwitter https://t.co/4ipKByaULi https://t.co/i4VffODqxJ
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
RT @CircAHA: Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across…
Systematic review & meta-regression analysis of the association between #triglyceride lowering & reduction of #CV risk across multiple #lipid lowering therapeutic classes: Learn more: https://t.co/c1Kzkv82jj #AHAJournals @marstonMD https://t.co/S1b6Keg3qy
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes | Circulation https://t.co/lDbNCtgqVi
RT @Nutradvance: New sys review: "Triglyceride lowering is associated with lower risk of major CV events, even after adjusting for LDL-C lo…
RT @Nutradvance: New sys review: "Triglyceride lowering is associated with lower risk of major CV events, even after adjusting for LDL-C lo…
RT @Nutradvance: New sys review: "Triglyceride lowering is associated with lower risk of major CV events, even after adjusting for LDL-C lo…
RT @Nutradvance: New sys review: "Triglyceride lowering is associated with lower risk of major CV events, even after adjusting for LDL-C lo…
New sys review: "Triglyceride lowering is associated with lower risk of major CV events, even after adjusting for LDL-C lowering" EPA omega-3 possibly protective: "Each 1 gram/d of EPA associated with a 7% relative risk reduction in major vascular events" https://t.co/qJFpSgZqRG
“In randomized controlled trials, triglyceride lowering is associated with lower risk of major vascular events...Furthermore, the benefits of marine-derived omega-3 fatty acids, particularly high-dose EPA, appear to exceed their lipid-lowering effects” https://t.co/ITnkC5pprx
2/2: The CV benefit of high-dose EPA may exceed lipid-lowering effect. @marstonMD @circAHA https://t.co/awVPfGAlcx
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Rev... - PubMed - NCBI https://t.co/hxOatTNb57
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials | Circulation https://t.co/ik1xSTs2EL
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
RT @marstonMD: Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected…
Is triglyceride lowering associated with CV risk reduction? Does high-dose EPA have CV benefit that exceeds what is expected by lipid-lowering alone? Our 49 trial meta-regression sheds light on these questions @circAHA @TIMIStudyGroup @BrighamFellows https://t.co/QXR1nXlg9p https://t.co/ZV0WOFWbAt
Fair and balanced review article on CVD risk reduction in TG-lowering trials with emphasis on omega-3s. Last couple of paragraphs were superb. Acknowledged both the awesomeness on icosapent ethyl in REDUCE-IT as well as the concerns and unknowns. https://t.co/bgb1EIxKym https://t.co/sZXTPdzcTU
Association Between TG Lowering and Reduction of CV Risk Across Multiple Lipid-Lowering Therapeutic Classes "Furthermore, benefits of marine-derived omega-3 fatty acids, particularly high-dose EPA, appear to exceed their lipid-lowering effects" $AMRN https://t.co/6RzCgdZnJc
RT @mbotana: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Clas…
Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials | Circulation https://t.co/KQAc2cDCou
@DrMarthaGulati @NadeenFaza @HMethodistCV @NorthwesternU @WilliamZoghbi @DipanJShah @almallahmo @DeBakeyCVedu @ChamsiPash @ACCinTouch @escardio @Heart_SCCT @SCAI @AHAScience @nstonedoc https://t.co/QR7B4tHbQR
@WilliamZoghbi @nstonedoc @ACCCardioEd @ACCinTouch @ASE360 @SCAI @CMichaelGibson @MyASNC @Heart_SCCT @ErinMichos @rblument1 @HeartOTXHeartMD @EricTopol @HMethodistCV https://t.co/QR7B4tHbQR
RT @SharonAConklin: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeut…
RT @SharonAConklin: Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeut…